Addressing deep pockets

in a different way

Up to now systemic antibiotics have been the norm to support SRP treatments, as today 7 to 11% of antibiotics consumed are prescribed by dentists. However this may be ineffective due to lack of patient compliance, carry potential side effects, become more expensive and enhance bacterial resistance. Gelcide brings a solution to this without altering your protocols.

Gelcide offers you an effective way to combat biofilm and bacterial infections by: Complementing your mechanical debridement in the deep periodontal pockets; Reducing the risk of infection in post-extraction areas and Ensuring wound closure.


How does
Gelcide work?


Gelcide’s exclusive patented formula creates a film over the infected area, sealing the pocket or wound and preventing contamination. However, given the fact that the mouth has several aggressive bacteria, the film is combined with an locally active adjuvant that protects its physical action during the length of the treatment.




No residuals; water soluble
Non-irritant and causes no discomfort
Chairside and local application
– Film action is protected by locally active ingredients that are not absorbed by the gastro-intestinal tract

Ease of application

  • Fluid mix that penetrates deep into the dental pocket before turning into film
  • Once applied, Gelcide ‘seals’ the pocket in seconds, remaining in the pocket as a dense gel and creating a protective film when making contact with air at the gingival level
  • Locally administered at the infection site, resulting in higher success rates than the sole use systemic antibiotics

Improved effectiveness

  • The physical film allows for the patient’s autologous regeneration

  • Gelcide’s protective action is preserved by locally active components

  • Biodegradable and active for 7 to 12 days

  • Treatment Safety: local application minimizes bacterial resistance and systemic antibiotics side effects

Patient benefits

  • Fast relief from bleeding and painless application within the first few days

  • Visible improvements

  • Locally active film protection instead od systemic treatment reduces the risk of side and long term secondary effects

  • Innovative approach that is less intrusive with the patient’s daily life

Treatment benefits

  • Securing patient compliance: as only doctor has complete control of the therapy compared to 60% or less compliance in systemic antibiotic

  • Gelcide’s periodontal application can be combined with regular SRP treatments with minimal treatment time increase

  • Increased chances of positive word of mouth and being perceived as very innovative

Gelcide Treatment
one drop, a full solution

Day 1

Thanks to easy application, rapid gelation and film creation, once Gelcide is applied into the dental pocket, the necessary amount of solution to protect the pocket is secured.

Days 2 - 10

Patented technology retains the protective film over the affected area. If there is bacteriological attack, the locally active components protect the film ensuring a safe self-regeneration.

Days 10 - 12

Patented technology retains the gel in the pocket for about 10 to 12 days depending of the pocket’s morphology. This allows for a quick recovery, while, the local action of the solution can delay the bacterial recolonization of the pocket.


Why Piperacillin - Tazobactam to protect the physical action of the film?


Periodontal patients present in most cases, aggressive bacteria in their mouth. These bacteria have already attack the soft tissues and the bone, and might be represented by several species. This means any protective film might also be attacked by these germs, and it’s therapeutic action might be at risk if not protected. That is why a broad spectrum protection, applied locally in non-therapeutical quantities was chosen. This protection also minimize side or secondary effects, improving treatment’s safety.


1) Najla Saeed Dar-Odeh,et al Antibiotic prescribing practices by dentists: a review Ther Clin Risk Manag. 2010; 6: 301–306
2) Laurestein M et al. Clinical and microbiological results following nonsurgical periodontal therapy with or without local administration of piperacillin/tazobactam. Clin Oral Invest. 2013; 1645–60
3) Loesche WJ et al. Metronidazole in periodontitis (IV). The effect on patient compliance on treatment parameters. J Clin Periodontol. 1993 Feb; 20(2): 96–104
4) Wu H et al. Strategies for combating bacterial biofilm infections. International Journal of Oral Sciences. 2015; 7: 1–7
5) Engesaeter LB et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2003; 74(6): 644–5
6) Rabbani GM et al. The effectiveness of subgingival scaling and root planing in calculus removal. J Periodontol 1981; 52: 119–23
7) Zheng H, et al. Subgingival microbiome in patients with healthy and ailing dental implants. Sci Rep. 2015;16;5:10948. Ata J Candel ME, Flichy AJ, Penarrocha D, Balaguer JF, Penarrocha DM. Periimplantitis: associated microbiota and treatment. Med Oral Patol Oral Cir Bucal 2011;16(7):e937-e943
8) Wellington ICU Drug Manual, Antibiotic sensitivity overview. Appendix 5

Manufactured by:

Lettenweg 132
CH-4123 Allschwil
+41 (0)61 225 60 68 / 69


Please insert user and password